Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Geisinger Health System and Celera, an Applera Corporation business, have entered into research collaboration with the aim of developing a diagnostic assay for the increased risk of non-alcoholic steatohepatitis.
Subscribe to our email newsletter
The collaboration will evaluate Celera’s numerous genetic findings in liver diseases, including the Cirrhosis Risk Score, in the Geisinger bank of more than 600 liver tissue and blood case-control samples donated from patients who have undergone bariatric weight loss surgery.
Bryan Allinson, director of Geisinger Ventures, said: “This academic entrepreneurial collaboration will help advance personalized medicine to practical clinical use, which is all part of Abigail Geisinger’s mission to make patient care ‘The Best’.”